Novartis Bags Chong Kun Dang’s HDAC6 Inhibitor In $1.3bn Deal
Potential In Cardiovascular Indications
Executive Summary
The deal marks the biggest out-licensing agreement ever for Chong Kun Dang, with the Swiss giant poised to explore the novel small molecule in various cardiovascular indications.
You may also be interested in...
Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
Global Health Leaders Highlight Pandemic Preparedness
At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.
Are Korean Biopharma Alliances Recovering After Gloomy Year?
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.